|
|
|
|
A double-blind,multi-center study was performed on patients with HTLV-I- associated myelopathy(HAM)to evaluate the therapeutic effect of treatment with natural interferon-a(HLBI).Forty-eight HAM patients were enrolled and treated with either 0.3 MU(n=15),1.0 MU(n=17),or 3.0 MU(n=16)of HLBI for 28 days.The therapeutic benefit in the 3.0-MU group was significantly higher than in the 0.3-MU group.There was no significant difference in the incidence of symptomatic side effects between groups.Abnormal laboratory data were obtained for some patients in the 1.0-MU and 3.0-MU groups; however,the treatment schedule could be continued in most patients.These results suggest that HAM patients may be safely treated with HLBI 3.0 MU every day for 4 weeks with favorable clinical effects. |
|